Origin Life Sciences, Inc. announced that its client, Origin Life Sciences, Inc. is about to launch an IRB-approved pilot clinical study to evaluate the treatment of Onychomycosis with its plasma-generated nitric oxide technology. ADMT provided engineering, regulatory and manufacturing services to Origin in the development of the IonoJet, which allows for targeted delivery of a plasma-generated NO stream produced from room air at the point of therapy. Onychomycosis, a fungal infection of the nail which occurs in approximately 14% of the adult population, is not just a cosmetic problem.

untreated it can cause pain, discomfort, and physical impairment, negatively impacting quality of life. Oral antifungal therapies are effective, but significant adverse effects limit their use. Topical antifungal therapies have fewer adverse events, but are less effective than oral antifungal therapies.

Therefore, an effective non-invasive therapeutic treatment option can have significant benefit for the tens of millions suffering from this condition. Origin intends to leverage the technology in the development of therapies for various therapeutic purposes including as an anti-infective, anti-inflammatory and tissue regenerative therapy for chronic wounds and skin and soft tissue infections. A randomized, controlled clinical study of the safety and dose-ranging of Origin's Ionojet was conducted on 83 patients with diabetic foot ulcers ("DFU") who had an inadequate response to standard of care, with promising results.

Origin intends to conduct a pivotal study on DFU and, if successful, to submit a pre-market approval application to the FDA. OnychomycOS is one of the next indications that Origin is pursuing, starting with this pilot study on 40 subjects presenting with fungal infected toenails, to be treated for 8 weeks with a 6-month follow-up, post therapy. Origin contracted ADMT's medical device engineering services for development of the Ionojet and for the production of study units used in the studies.

ADMT developed and manufactured the Ionojet in its FDA-Registered, ISO-13485 Certified medical device development and manufacturing facility.